Provider: View Press Release
Type: Link
Title: New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline | GSK
Description: New GSK to positively impact health of >2.5 billion people next 10 years
Provider: View Press Release
Type: Link
Title: ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV | GSK
Description: Halozyme’s technology provides more “shots on goal” to create ultra long-acting HIV medicines with dosing intervals of 3 months or longer
Provider: View Press Release
Type: Link
Title: GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab | GSK
Description: U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.
Provider: View Press Release
Type: Link
Title: GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations | GSK
Description: GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
Provider: View Press Release
Type: Link
Title: GSK to showcase scientific advances and progress in oncology at ASCO and EHA | GSK
Description: GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.
Provider: View Press Release
Type: Link
Title: Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate | GSK
Description: Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021